Several bispecific molecules such as diabodies, IgG-like tetravalent Di-diabodies, IgG-scFv fusion proteins, and bispecific AdnectinsTM have been developed to target tumor mediated receptors such as members of the epidermal growth factor (EGF) receptor family, i.e., EGFR, HER2, HER3, and HER4,45 and the insulin-like growth factor 1 receptor (IGF-1R; Tao et al., 2007; Kontermann and Brinkmann, 2015). The gene discussed is IGF1R; the disease is neoplasm.